About Sio Gene Therapies, Inc.
Sio Gene Therapies Inc., together with its wholly owned subsidiaries, is a clinical-stage company focused on developing gene therapies for neurodegenerative diseases. The Company is developing a pipeline of product candidates for the treatment of these debilitating diseases, including Parkinson's disease, GM1 gangliosidosis and GM2 gangliosidosis (including Tay-Sachs disease and Sandhoff disease). The Company’s subsidiaries include Axovant Holdings Ltd, Axovant Sciences Inc, Axovant Sciences GmbH, Axovant Sciences Amercia, Inc., Axovant Treasury Holdings, Inc., Axovant Treasury, Inc and Axovant Sciences Europe Ltd. The Company’s clinical-stage programs include AXO-Lenti-PD, AXO-AAV-GM1 and AXO-AAV-GM2 program.